Abstract
The anticancer mediators claim their activity in liquid form as a biocompatible and use in bios stems, which are mostly collected in fluid form. Control on the stability of metal oxide nanoparticles in parallel reducing the effect of large amount on their biological and cytotoxicity activities, remains a challenge. Here anticancer activity and cytotoxicity zinc oxide nanoparticles (NPs) have been presented that are coated with folic acid (F.A) and polyethylene glycol (PEG). The nanoparticles were synthesized by wet chemical method and characterized by x-ray diffraction; scanning electron microscopy and Fourier transform infrared spectroscopy. The cytotoxicity studies were performed on HepG2 cells.MMT assay was used to check the cell viability. The PEG and F.A capped ZnO NPs have shown reduction in cytotoxicity as compare to bare ZnO nanoparticles.
Highlights
Since the last decade, the nanotechnology gained more interest of scientists and researchers around the world
Elje et al checked the cytotoxicity of bare zinc oxide (ZnO) NPs on HepG2 cells and their findings show the dependence of cytotoxicity on the concentration of Zinc oxide nanoparticles (ZnO NPs) [15]
No peak related to impurity phase was detected, which suggested that pure zinc oxide nanoparticles with high crystalline quality have been fabricated successfully
Summary
The nanotechnology gained more interest of scientists and researchers around the world. Jevapatarakul D., et al synthesized ZnO NPs by green method and exposed on skin cancer cells (A431) to analyze their cytotoxicity. They concluded that the cytotoxicity of ZnO NPs is dose and concentration dependent [16]. Et al studied the cytotoxicity on bare ZnO NPs on HepG2 cells They concluded that the cytotoxicity depends on size of NPs and concentration [18]. The presented work focuses on the issue of ZnO NPs by capping with polymers, folic acid (F.A) and polyethylene glycol (PEG) and evaluation of their cytotoxicity towards HepG2 cells
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
